Acetyl Lysine(10B10)Mouse Monoclonal Antibody

Acetyl Lysine(10B10)Mouse Monoclonal Antibody

Cat: AMM04164
Size:50μL Price:$118
Size:100μL Price:$220

Size:200μL Price:$380
Application:WB,IHC,ICC/IF,IP

Reactivity:Species independent
Conjugate:Unconjugated
Optional conjugates: Biotin, FITC (free of charge).
See other 26 conjugates.

Gene Name: Category: Mouse Monoclonal Antibody Tags:

Summary

Production Name

Acetyl Lysine(10B10)Mouse Monoclonal Antibody

Description

Mouse monoclonal Antibody

Host

Mouse

Application

WB,IHC,ICC/IF,IP

Reactivity

Species independent

 

Performance

Conjugation

Unconjugated

Modification

Acetylated

Isotype

IgG

Clonality

Monoclonal

Form

Liquid

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Buffer

PBS, pH 7.4, containing 0.5%protective protein, 0.02% New type preservative N as Preservative and 50% Glycerol.

Purification

Affinity purification

 

Immunogen

Gene Name

Alternative Names

Gene ID

SwissProt ID

 

Application

Dilution Ratio

WB 1:1000-1:2000,IHC 1:200-1:500,ICC/IF 1:50-1:200,IP 1:100-1:200

Molecular Weight

 

Background

Acetylation of lysine, like phosphorylation of serine, threonine or tyrosine, is an important reversible modification controlling protein activity. The conserved amino-terminal domains of the four core histones (H2A, H2B, H3, and H4) contain lysines that are acetylated by histone acetyltransferases (HATs) and deacetylated by histone deacetylases (HDACs). Signaling resulting in acetylation/deacetylation of histones, transcription factors, and other proteins affects a diverse array of cellular processes including chromatin structure and gene activity, cell growth, differentiation, and apoptosis. Recent proteomic surveys suggest that acetylation of lysine residues may be a widespread and important form of posttranslational protein modification that affects thousands of proteins involved in control of cell cycle and metabolism, longevity, actin polymerization, and nuclear transport. The regulation of protein acetylation status is impaired in cancer and polyglutamine diseases , and HDACs have become promising targets for anti-cancer drugs currently in development.

 

Research Area

   💬 WhatsApp